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with diamw10 nm can slowly penetrate through the full thickness of
cartilage. But a highly positively charged globular protein, Avidin (Av)
(66 kDa,w7nm diam) rapidly penetrated into the deep zone of bovine
cartilage within 24 h, resulting in 400x higher uptake than its neutral
same-sized counterpart, NeutrAvidin (Nu). With the goal of using Av asa nanoparticle drug delivery carrier into cartilage, we injected it into
healthy rat knee joints to investigate uptake kinetics, tissue distribution,
and retention in vivo. We also studied the effects of Av on chondrocyte
viability, sGAG content, and PG biosynthesis rates using bovine cartilage
in vitro to determine the safe limit of Av for drug delivery.
Methods: Knee joints of healthy Fisher rats were injected with 50 ml of
50mM Av or Nu-Texas Red. Contralateral knees were used as controls.
Rats were sacriﬁced at 6 h, 1d, 4d, 7d, and 5 tissue types were extracted:
cartilage [C] (patellar groove, femoral condyle and tibial plateau);
menisci [M]; ligaments [L]; tendons (patellar [PT] and quadriceps [QT]);
and femoral bone. Samples were desorbed in 10x PBS for 48 h at 37C to
fully release Av into the bath. Solute concentration was measured and
normalized by tissue dry weight (Fig 1, Mean þ/- SD; N ¼ 6 rats per
condition). Av half-life was calculated in each tissue by ﬁtting expo-
nential decay curves to Fig 1 data, and then plotted versus tissue sGAG
content (measured via DMMB, Fig 2, blue lines depict 95% conﬁdence).
Dose dependent Av biological response (in-vitro): Bovine cartilage disks
(3 x 1mm) were cultured with a one-time 48 h dose of Av (0, 100nM,
1mM, 100 mM) over 10 days. Upon termination of culture, disks were
stained with ﬂuorescein diacetate (green, for viable cells) and propi-
dium iodide (red, for dead cells, [Fig 3]). Samples were digested and
sGAG released to the medium and retained in cartilage was measured
via DMMB; proteoglycan and protein synthesis rates were measured 48
h before termination of cultures (via sulfate and proline radiolabel
incorporation respectively), and normalized to wet weight (Fig 4B-C).
Results: Av penetrated rapidly into all tissues within 6 h (Fig 1). Av
concentration in cartilage decreased to 10.3% and 4.1% of the 24 h value
by 4d and 7d respectively. Despite similar size, no Nu was present at 24
h in cartilage. A positive correlation (R2¼0.83) between Av half-life and
sGAG content in different knee tissues conﬁrmed effects of electrostatic
interactions (Fig 2). There was no effect of Av dose on cell viability in
bovine cartilage compared to untreated controls (Fig 3), and no sig-
niﬁcant difference in the cumulative sGAG loss to medium between the
untreated control,100nM and 1 mMAv treated conditions, while 100 mM
Av resulted in w2x higher sGAG loss compared to controls (Fig 4A).
There was no change in rates of protein or sGAG synthesis with
increasing Av dose.
Conclusions: Our results show that electrostatic interactions aug-
mented Av transport enabling distribution throughout the joint and
penetration into tissues before being cleared by lymphatics. Av was
retained inside rat joints for 7 days with a half-life of 29 h in cartilage,
whereas Nu exhibited complete clearance within 24 h of i.a. injection.
We previously reported >90% retention of Av in bovine cartilage (in
vitro) for at least 15 days. A drop in retention in vivo is expected because
of the presence of convective transport & lymphatics. The 4.1% retention
at 7d in rat studies is most likely due to 10x lower thickness of rat
cartilage compared to bovine. Since the diffusion-binding time constant
scales as the square of tissue thickness, Av transport out of rat cartilage
is expected to be w100x faster, explaining the shorter retention dura-
tion overall. A carrier like Av (safe dose <1 mM) can transport low MW
drugs like dexamethasone into cartilage at a fast rate, bind with neg-
atively charged groups in tissue, thereby creating a drug depot inside
cartilage
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Purpose: Osteoarthritis (OA) progresses via a feed-forward cycle in
which inﬂammation leads to the up-regulation of catabolic enzymes
that cleave the extracellular matrix (ECM) components; the ECM frag-
ments further stimulate inﬂammation. The degradation of aggrecan is a
critical early event in OA due to aggrecan’s ability to protect other ECM
components from degradation and support the compressive strength of
cartilage. We have developed a class of ECM-targeting proteoglycan
mimics, and here characterize an aggrecan mimic (mAGC) in its ability
to replace the functions of native aggrecan and halt the progression
of OA.
Methods: We synthesized mAGC by ﬁrst oxidizing chondroitin-6-sul-
fate (CS) and then conjugating hyaluronic acid-binding peptide to the
CS backbone. Three sets of experiments were performed. First, aggrecan
was removed from bovine cartilage plugs followed by treatment with
mAGC. Compressive strength of the tissue was assessed, and gene
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inﬂammatory signal. Second, intact cartilage plugs pre-treated with
mAGC were cultured with synovial ﬂuid from OA patients undergoing
total knee replacement. Sircol and dimethylmethylene blue assays were
used to detect release of ECM components from the plugs, and the
protein and gene expression of inﬂammatory markers and catabolic
enzymes were measured. Finally, an in vivo rat model of OAwas used to
test the ability of mAGC to suppress OA progression.
Results: Here we examine the aggrecan mimic in both ex vivo cartilage
tissue models and an in vivo animal model. Aggrecan-depleted cartilage
plugs had only approximately 30% of the compressive strength of intact
plug. mAGC was able to diffuse into the cartilage tissue and restore the
compressive strength to 90% of the intact healthy cartilage. In addition
to the mechanical effects, depletion of aggrecan resulted in an increase
in catabolic gene expression by the chondrocytes that was further
ampliﬁed with additional inﬂammatory stimuli. Treatment with mAGC
resulted in chondrocyte gene expression of catabolic enzymes at the
same level as healthy intact cartilage, both with and without inﬂam-
matory stimulation over 21 days. Intact cartilage plugs exposed to
osteoarthritic synovial ﬂuid resulted in high degradation of ECM com-
ponents as measured by release into the culture media over an 8-day
period. A single pre-treatment with mAGC decreased this degradation
to levels similar to those in healthy cultured controls. Further, inﬂam-
mation and catabolic enzymatic gene expressionwas lowered in treated
plugs to near healthy levels, even in the presence of the inﬂammatory
and enzyme-rich synovial ﬂuid. The data indicates that by providing
robust protection against degradation and restoring the mechanical
environment, the pro-inﬂammatory signals that cause upregulation of
the degrading enzymes are decreased. In an aggressive rat model,
mAGC was able to keep catabolic enzyme levels closer to healthy levels,
preserve the proteoglycan content of cartilage tissue, and decrease bone
loss as compared to untreated controls.
Conclusions: This study provides the ground-work for development of
an intra-articular therapy that reduces fragmentation of key extrac-
ellular matrix components and restores the mechanical environment of
the cartilage tissue, resulting in decrease in inﬂammation and catabolic
enzyme production. The therapy has the potential to promote a healthy
environment for future tissue regeneration. mAGC is the ﬁrst ther-
apeutic to speciﬁcally target the ECM components of cartilage to offerrobust protection from the numerous destructive factors present in OA.
Further, mAGC is the only therapeutic that targets the mechanical
environment of cartilage tissue. Ongoing work is exploring the efﬁcacy
of mAGC in preventing OA in a spontaneous guinea pig model.
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Purpose: Based on small to moderate effect sizes for the wide range of
symptomatic treatments in osteoarthritis (OA) and on the hetero-
geneity of OA patients, treatment guidelines for OA have stressed the
need for research on clinical predictors of response to treatment. Meta-
analysis to quantify the effect modiﬁed by the predictors using Indi-
vidual Patient Data (IPD) fromworldwide available trials is proposed as
gold standard. The OA Trial Bank initiative therefore evaluated the
efﬁcacy of intra-articular (IA) glucocorticoids for knee and hip OA for
subgroups of patients with severe pain, and inﬂammation on short term
follow-up using IPD from existing trials.
Methods: Study selection
Randomized trials evaluating one or more IA glucocorticoid preparation
in patients with knee or hip OA, published from 1995 up to June 2012
were selected from the existing literature. All IA glucocorticoid prepa-
rations used for treatment of OA of the knee or hip in humans compared
with control treatments, including placebo, IA hyaluronan/hylan and
tidal irrigation were included. The presented preliminary analyses will
include the comparison between IA glucocorticoids and placebo, since
data included in this comparison are complete.
Individual data obtained from original trials included patient charac-
teristics (age, gender, BMI), disease characteristics (duration of com-
plaints, KL score, type of OA, inﬂammatory signs and pain severity) and
outcomes measured (pain severity, physical functioning and patient
global assessment).
Data collection and transfer: Corresponding authors of eligible trials
were approached and asked to cooperate in this project. All data-
deliverers signed a license agreement to guarantee legal issues between
the OA Trial Bank and data-deliverers. All anonymized data were
transferred to a secured database.
Data analyses: All analyses were performed following our published
protocol. The primary outcome was pain severity at short-term follow-
up (up to 4 weeks), converted to a 0 to 100 scale. The subgroup factors
assessed included severe pain (>70 points on a 0-100 scale) and signs of
inﬂammation (dichotomized following study speciﬁc cut-off points).
To assess the subgroup effects, a multilevel regression analysis (random
trial intercept, restricted maximum likelihood algorithm) was applied
to calculate the interaction effects (indicator for difference in response
on treatment for the subgroups). Analyses were adjusted for baseline
pain severity, age, gender and BMI. Interaction effects with P < 0.05
were considered statistically signiﬁcant.
Results: Seven published randomized clinical trials including 309
patients were included in the OA Trial Bank by 1 December 2013
(additional data of 360 patients is afﬁrmed). Of these, four studies with
225 patients (mean age 64.5(SD11.2); 56% male; BMI 28.4(SD4.9);
duration of complaints 86(SD122) months, 60% knees and 40% hips)
compared glucocorticoids with placebo. Severe pain at baseline was
reported by 28.1% of the patients, and inﬂammatory signs (reported by
three studies; two based on ultrasound (synovitis/effusion measured in
millimeters) and in one study measured by evidence of effusion by
physical examination) were present in 51.7% of the subjects.
The overall estimate of the main effect of IA glucocorticoid injection
compared to placebo on short-term pain severity was 22.8 (95%CI13.2-
